Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOTRONIK Releases Line-Extension of Orsiro Hybrid Drug Eluting Stent

Published: Tuesday, September 03, 2013
Last Updated: Tuesday, September 03, 2013
Bookmark and Share
The highly deliverable Orsiro stent is now available in lengths up to 40 mm to address a wider range of lesions.

BIOTRONIK has announced the market release of new 35 and 40 mm versions of Orsiro, the industry’s first hybrid DES (Drug Eluting Stent) featuring a bioabsorbable polymer. BIOTRONIK now offers one of the longest drug-eluting stents on the market across all diameters.

The Orsiro 40 mm was first implanted by Dr. Heinz-Joachim Büttner, MD of University Heart Center, Bad Krozingen, Germany. "The low strut thickness and good deliverability of Orsiro is even more evident in long lengths,” commented Dr. Büttner "With the addition of the new sizes, there is now an Orsiro available for almost every case."

The efficacy and safety of Orsiro was recently demonstrated in two high profile studies, BIOFLOW-II and BIOFLOW-III, which showed that Orsiro performs as best in class.

The robust clinical evidence of the BIOFLOW-II study was presented at the 2013 EuroPCR congress by principal investigator, Prof. Stephan Windecker, MD of University Hospital Bern, Switzerland.

BIOFLOW-II is a prospective, international, multi-center, randomized trial which evaluated the safety and efficacy of Orsiro compared to Abbott’s XIENCE PRIME™.

At nine months, the results for the primary endpoint in-stent late lumen loss were 0.10 ±0.32 mm in the Orsiro arm and 0.11 ±0.29 mm in the XIENCE PRIME™ arm evaluated by an independent core laboratory and confirming the non-inferiority hypothesis (p-value for non-inferiority <0.0001).

No significant differences were reported for the clinical end-points at nine months. Additionally no stent thrombosis was reported in either arm.

“With the addition of the 35 and 40 mm lengths, Orsiro now has a complete size range. The new lengths, in combination with the great deliverability, means that physicians can use Orsiro across a wider range of lesions,“ commented Alain Aimonetti, Vice President Sales and Business Development, BIOTRONIK Vascular Intervention.

Aimonetti continued, “The impressive results from the BIOFLOW-II and BIOFLOW-III trials demonstrate the excellent performance of Orsiro and firmly place it at the forefront of the stent market.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves First Single-Lead ICD with Atrial Sensing
BIOTRONIK’s Lumax DX system could help the 50,000 patients each year who may benefit from atrial sensing, without pacing indication.
Tuesday, September 17, 2013
BIOTRONIK Orsiro Hybrid DES Lives Up to Abbott’s XIENCE PRIME™
Positive 9 month results from BIOFLOW-II clinical trial and 12 month results from BIOFLOW-III registry presented at EuroPCR congress.
Tuesday, July 09, 2013
BIOTRONIK Home Monitoring® Reduces Inappropriate ICD Shocks by 52%
ECOST trial results published in European Heart Journal.
Friday, December 21, 2012
BIOTRONIK Announces 12-Month Results from 4EVER Study
Results show strong evidence of benefits for lower limb intervention when using Pulsar stents.
Monday, November 19, 2012
First CRT-D Patient Enrolled in the EuroEco ICD/CRT-D Trial
Study to assess the economic effects of BIOTRONIK Home Monitoring®.
Tuesday, July 24, 2012
Large-Scale BIOTRONIK SPIRIT-ICD Study Enrollment Complete
SPIRIT-ICD study explores benefits of intensified diagnostic follow-up and timely therapeutic intervention for high-risk patient group.
Monday, July 09, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!